Woburn, MA – According to filings with the U.S. Securities and Exchange Commission, Axial Therapeutics is raising $37,806,866.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Jeffrey Young played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Axial Therapeutics
Axial Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders. The company is leveraging its expertise in the gut-brain axis and its unique drug development platform to advance novel therapies that have the potential to transform the treatment paradigm in neurodegenerative diseases. Axial Therapeutics is fundamentally changing the treatment of neurological diseases and disorders by harnessing groundbreaking science in the microbiome-gut-brain axis. The technical underpinning of Axials unique gut-targeted therapeutic approach is a robust platform for the identification of new disease targets and the design and delivery of small molecule drugs for neurodegenerative diseases and neurodevelopmental disorders. Axials scientific framework provides the platform and data for establishing the mechanistic role of the gut-brain axis in neurological disease pathology and its influence on disease symptoms, including behavior, motor function and even the gastrointestinal problems frequently found in people with neurological diseases and disorders.

To learn more about Axial Therapeutics, visit http://axialtx.com/

Contact:
Jeffrey Young, Chief Financial Officer
781-701-8484
jeffrey@axialtx.com
https://www.linkedin.com/in/jeffrey-young-39489718/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved